SGLT2 Inhibitors Should NOT Be Used in Infants with Dilated Cardiomyopathy
SGLT2 inhibitors are not recommended for infants with DCM due to complete absence of safety and efficacy data in this age group, lack of regulatory approval, and significant developmental concerns specific to infancy.
Evidence-Based Rationale
Guideline Recommendations for Pediatric DCM
The American Heart Association's 2016 scientific statement on pediatric DCM explicitly recommends following guideline-directed medical therapy for adult HF patients using diuretics, β-blockers, ACE inhibitors, and other medications as appropriate 1. Notably, SGLT2 inhibitors are completely absent from these recommendations, as they did not exist as HF therapy at the time and have never been studied in infants.
The guideline emphasizes that evidence in the pediatric population is already limited for established therapies, making the use of novel agents without any pediatric data particularly problematic 1.
Age-Specific Concerns in Available Pediatric Data
Recent emerging research on SGLT2i in pediatric HF reveals critical age limitations:
- The youngest patients studied were school-age children, with median ages of 11 years 2 and 6-15 years in reported cohorts
- No data exists for infants (defined as <1 year of age)
- Current pediatric studies explicitly focus on patients "less than 19 years" but practical enrollment skews heavily toward older children and adolescents 2, 3
Developmental and Safety Concerns Specific to Infants
The available pediatric literature highlights safety concerns that would be magnified in infants:
- Dehydration risk: SGLT2i cause osmotic diuresis, particularly dangerous in infants with limited fluid reserves and immature renal function 3, 4
- Acute kidney injury: Documented in pediatric studies, with notable decreases in GFR and increases in serum creatinine 3. Infant kidneys are still developing, with GFR not reaching adult levels until age 2
- Infections: Genital candidiasis and urinary tract infections reported in children 2, 3; infants have immature immune systems and cannot communicate symptoms
- Growth and neurodevelopmental effects: Explicitly cited as pediatric-specific concerns requiring study 4, particularly critical during infancy when brain development is most rapid
Regulatory Status
The FDA has mandated pediatric studies for empagliflozin, but these are not yet completed 4. Current regulatory waivers have historically excluded the pediatric population entirely, and no SGLT2i carries approval for use in infants.
Clinical Algorithm for Infant DCM Management
For infants with DCM, use the established pediatric HF regimen 1:
First-line therapy:
- Diuretics (furosemide) for volume management
- ACE inhibitors (enalapril, captopril)
- Digoxin for inotropic support
Consider adding:
- β-blockers (carvedilol, though evidence is limited even for this in infants)
- Mineralocorticoid receptor antagonists (spironolactone)
For severe/refractory cases:
- Mechanical circulatory support (ECMO, VAD) as bridge to transplant 1
- Heart transplantation evaluation
Rule out reversible causes:
- Anomalous coronary arteries
- Metabolic disorders
- Genetic testing (LMNA, SCN5A if conduction disease present) 1
Critical Pitfalls to Avoid
- Do not extrapolate adult HF data to infants: Pediatric DCM differs fundamentally, with higher rates of spontaneous recovery and different etiologies 1
- Do not use SGLT2i off-label in infants: The risk-benefit ratio is completely unknown and potentially unfavorable given developmental vulnerabilities
- Do not delay proven therapies: While SGLT2i show promise in older children, infants need immediate treatment with established agents
Future Considerations
Ongoing trials (EMPA-KIDNEY-Kids, DOUBLE-PROTECT) may eventually provide pediatric data 4, but these studies are unlikely to include infants initially. Until age-appropriate safety and efficacy data become available, SGLT2i remain investigational even in older children and contraindicated by absence of evidence in infants.